Umbilical cord derived mesenchymal stem cell therapy for osteoarthritis: a consolidated review by Zuo, Jianwei et al.
Sains Malaysiana 49(2)(2020): 335-341
http://dx.doi.org/10.17576/jsm-2020-4902-11
Umbilical Cord Derived Mesenchymal Stem Cell Therapy for Osteoarthritis: A 
Consolidated Review
 (Tali Pusat Terbitan Terapi Sel Stem Mesenkima untuk Osteoartritis: Suatu Ulasan Lengkap)
JIANWEI ZUO, CHEN CHEN, XINTAO ZHANG & WENTAO ZHANG*
ABSTRACT
Osteoarthritis (OA) is a leading cause of degenerative disease and is the most common persistent condition worldwide. 
The common burden imposed by OA significantly damages the articular cartilage, which results in pain and seriously 
impacts the quality of life in the affected people. Disease progression is assumed to increase with obesity and aging. The 
current therapies include weight loss, activity adjustment, traditional pain management and replacement of the affected 
joint. To overcome these limitations, recently, cell-based therapies mainly Umbilical cord derived Mesenchymal stem 
cell (UC-MSC) have become an attractive cell source for an allogeneic mesenchymal stem cell to repair and regenerate 
the structure and function of articular tissues. Although the mechanism is not clearly defined, it is believed that the 
paracrine signaling, inflammatory response, and immunomodulatory role of UC-MSCs play a crucial role in developing 
a treatment approach of OA. The purpose of this review was to outline the advantages of using UC-MSCs in treating OA. 
This review also discusses the possible hurdles that stand in the way of successful implementation of UC-MSC as a 
routine treatment regimen for OA.
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ABSTRAK
Osteoartitis (OA) adalah penyebab utama penyakit degeneratif dan merupakan keadaan yang paling biasa di seluruh 
dunia. Beban umum yang disebabkan oleh OA dengan ketara merosakkan artikul rawan yang mengakibatkan kesakitan 
dan memberi kesan serius terhadap kualiti hidup orang yang mengalaminya. Janjang penyakit ini dianggap meningkat 
dengan keobesan dan penuaan. Terapi semasa termasuklah penurunan berat badan, pelarasan aktiviti, pengurusan 
sakit secara tradisi dan penggantian sendi yang terjejas. Untuk mengatasi keterbatasan ini, terbaru, terapi berasaskan 
sel terutamanya tali pusat terbitan terapi sel stem mesenkima (UC-MSC) telah menjadi sumber sel yang menarik untuk 
sel stem alogen mensenkima untuk membaiki dan menjana semula struktur dan fungsi tisu artikul. Walaupun mekanisme 
itu belum ditakrifkan dengan jelas, dipercayai bahawa isyarat parakrin, tindak balas keradangan dan peranan 
imunomodul UC-MSC memainkan peranan penting dalam membangunkan pendekatan rawatan OA. Tujuan kajian ini 
adalah untuk menggariskan kelebihan menggunakan UC-MSC dalam merawat OA. Ulasan ini juga membincangkan 
kemungkinan halangan yang berlaku dalam pelaksanaan UC-MSC dengan jayanya sebagai regimen rawatan rutin 
untuk OA.
Kata kunci: Osteoartitis; sel stem alogen; sel stem mesenkima; tisu tali pusat 
INTRODUCTION
Osteoarthritis is a common degenerative and inflammatory 
disease that affects the cartilage, joint tissues, and 
subchondral bone. It results in bones scuff, which induces 
rigidity, pain, and impaired movements in all ages (Hatched 
et al. 2017). Half of the world’s population aged 60 years 
and above have asymptomatic OA and the percentage of 
OA is higher with women (Arthritis Information 2017). 
This might be coupled with risk factors, including lack of 
exercise, obesity, occupational injury, bone density, genetic 
tendency, trauma, and aging (Blagojevic et al. 2010; 
Silverwood et al. 2015). In addition, the increase in the 
level of oxidative stress and senescence related secretory 
factors are related to the pathogenesis of OA (Li et al. 
2013). 
At present, the literal cause of OA and effective 
treatment to restore the original structure and function of 
damaged articular cartilage remain out of reach (Mobasheri 
et al. 2014). Current treatment modalities for OA are 
expected to reduce the pain rather than disease modification. 
Furthermore, the existing pharmaceutical treatments are 
inadequate and can have redundant side effects (Bagga et 
al. 2006). Surgical treatments mainly focus on relieving 
the pain and restoring joint function, but has limited 
benefits on degenerative changes that take place (Vaishya 
et al. 2016). Meanwhile, total knee arthroplasty (TKA) is 
the most commonly performed procedure in the elderly 
and advanced OA. However, the TKA procedure does not 
recover the patients completely. In particular, the results 
for younger patients who expect to have anactive lifestyle 
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after surgery are minimal. Patient satisfaction remains at 
only 80% to 83% after TKA (Kennedy et al. 2013; 
Robertsson et al. 2000). In recent years, the numbers and 
costs of TKA have increased dramatically - in 2001, the 
procedure cost an average of $25,500 per surgery but in 
2012 it cost $52,000 per surgery (Centeno et al. 2015).
In recent years, there has been increasing interest in 
the use of cell-based therapy for the treatment of OA. In 
particular, autologous chondrocyte implantation in 
damaged OA cartilage is the most preferred therapeutic 
approach. Although it is an obscure procedure to harvest 
and culture the chondrocytes from the elderly people (de 
Windt et al. 2014), the recent advances in stem cell 
engineering have progressed towards its development. 
Mesenchymal stem cell (MSCs) have gained interest 
because they are considered to be readily available and are 
able to differentiate into chondrocytes. The multi-lineage 
differentiation potential of MSCs is considered to possess 
an added advantage of treating cartilage defects (Orth et 
al. 2014). Originally, bone marrow was considered as a 
key resource of MSCs; however, MSCs derived from bone 
marrow significantly decline with aging. Studies have 
reported that MSC can be generated from liver, heart, skin, 
umbilical cord, and cord blood. Among these, umbilical 
cord derived MSCs stand out because they can grow 
infinitely, pose lesser ethical issues and can be rapidly 
explanted under in vitro conditions (Rao & Matson 2001; 
Subramani et al. 2016; Wang et al. 2004). However, the 
maintenance of the chondrogenic characteristics of 
differentiated stem cells, their combination with resident 
tissue, and impersonating the natural strength presents a 
challenge when adopting stem cell therapy for OA 
(Diekman & Guilak 2013). In this review, we have 
summarized the recent position of UC-MSC therapies in 
OA and we have also discussed the potential areas of further 
research needed in regenerative medicine.
CHONDROGENIC DIFFERENTIATION OF UC-MSC
MSCs have an added advantage in the field of tissue 
regeneration and cartilage repair because they can retain 
their differentiation potency after ex vivo expansion. 
Nevertheless, the stemness, proliferation and differentiation 
potency vary based on the source, environment, signaling 
molecules, physical and chemical factors (Lavrentieva et 
al. 2013). Studies have shown that MSCs have been isolated 
from different sources and display different potentials to 
differentiate towards certain cell lineages (Stockmann et 
al. 2012; Wen et al. 2013; Zuk et al. 2002). MSCs derived 
from adipose tissue (AD) and bone marrow (BM) express 
cartilage-specific genes and proteins, which include 
aggrecan and Type II collagen. However, the chondrogenic 
potential is statistically weaker in terms of matrix formation 
and cell morphology in AD when compared to the bone 
marrow-derived MSCs (Estes et al. 2010; Im et al. 2005; 
Payne et al. 2010; Scharstuhl et al. 2007). UC-MSCs have 
an advantage over BM-MSCs because they show higher 
chondrogenic potential and collagen production three times 
higher than BM-MSC (Wang et al. 2009a). In addition, stem 
cell derived from UC has additional advantages compared 
to other sources. They recline between embryonic and adult 
stem cells on the development map, they do not induce 
tumorigenesis, and are hypoimmunogenic (Kim et al. 
2013). Meanwhile, hyaluronate naturally occurs within the 
cartilage and synovial fluid. The UCs naturally contain 
hyaluronic acid, which adds advantage to use UC- MSC 
for chondrogenic differentiation (Can & Karahuseyinoglu 
2007) because hyaluronate has special healing actions and 
is already a routine therapeutic option for various 
complications.
Recently, Kwon et al. (2016) demonstrated that MSCs 
from amnion (AMSCs), chorion(CMSCs), and umbilical 
cord (UC-MSCs) are able to differentiate into chondrocyte-
like cells. Their study concluded that prenatal tissue is an 
excellent source of MSCs in the terms of proliferation and 
differentiation into osteocytes, adipocytes, and 
chondrocytes. They are predicted to be superior sources 
to BM-MSCs due to their innate differentiation potency and 
HLA-G expression. When a comparative study between 
human UC-MSC and BM-MSC for cartilage tissue 
engineering was performed, it was detected that UC-MSCs 
showed strong upregulation of cartilage-specific transcript 
expression and showed higher Type II collagen synthesis 
than BM-MSC at both transcript and protein levels (Reppel 
et al. 2015). Fong et al. (2012) showed that the WJ-MSC 
cultured with nanofibrous substrates enhanced chondrogenic 
differentiation and these authors were able to get 
upregulated with the production of hyaluronic acid and 
GAGs, as well as the expression of key genes as SOX9, 
COMP, Collagen Type II and FMOD. The results of the 
various approaches performed so far utilizing the UC-MSCs 
are tabulated in Table 1, which shows effective chondrogenic 
differentiation.
POSSIBLE MECHANISM OF UC-MSC IN OA
Articular cartilage is typically known as diarthrodial joints 
and is particularly made up of hyaline cartilage that 
comprises chondrocytes residing in a dense extracellular 
matrix (ECM), to facilitate smooth and painless movement. 
The mesenchymal origin of chondrocytes plays a vital role 
in protecting and maintaining the anatomical structure of 
cartilage and contributes about 2% of the total volume of 
the cartilage (Lee & Wang 2017). In the case of any injury, 
owing to the lack of blood vessels in the articular region 
and the limited potential of the chondrocytes replication, 
the damage results in poor cartilage regeneration. The 
pathophysiology of OA indicates that OA is not only 
associated with cartilage damage but is also associated 
with the damage of synovium and subchondral bone 
(Brandt et al. 2009; Mobasheri et al. 2014). Therefore, the 
therapeutic approach should be designed to target multi-
cellular regeneration in OA.
Emerging evidence claims that cell-based therapy is 
a more promising therapeutic tool for OA than the current 
regimen dealing with pain management. In particular, 
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mesoderm lineage of MSC has the ability to differentiate 
into a bone cell (osteocyte) and cartilage tissue 
(chondrocyte). Thus, MSC has come to the fore of modern 
science for OA. It has been reported that MSC proliferation, 
differentiation potential, and host survival are age 
dependent (Pelttari et al. 2006; Steinert et al. 2007). With 
this limitation, patient specific (autologous) MSC therapy 
may not be advisable to meet the requirement. To overcome 
this issue, an outsource of (allogeneic) MSC may appear 
to be an alternative or tangible ‘off-the-shelf’ source for 
OA. Among those, umbilical cord derived MSC (UC-MSC) 
stands out because of the infinite availability of samples, 
lesser ethical issues, and rapid in vitro isolation and 
expansion. Various clinical studies have implicated the 
significance of UC-MSC in cartilage regeneration for the 
treatment of OA (Chang et al. 2018, 2016; Matas et al. 
2019). Although a large number of studies suggested that 
umbilical cord derived MSCs have the potential to improve 
the overall condition of OA, their mechanism of action has 
not been completely explored. The paracrine effect of UC-
MSC is considered as one of the crucial factors found in 
cartilage regeneration. In an important study by Chang et 
al. (2018), HUMSC derived conditional media supported 
and recovered the chondrocytes from impaired proliferation 
and also protected them from caspase-3 mediated apoptosis 
under laboratory conditions. Specifically, intra-articular 
injection of UC-MSC assisted the repair and regenerated 
cartilage in OA induced mice model. In addition, Zhang et 
al. (2018) also demonstrated that UC-MSC potentially 
improves the cartilage regeneration in OA induced canine 
model, which promoted the chondrocyte proliferation and 
reduced or inhibited the inflammatory response. It has also 
been reported that UC-MSCs promoted the OA chondrocytes 
proliferation and inhibited the inflammatory cytokines 
(Wang et al. 2018b).  In addition, MSCs could adjust the 
cell signaling environment, increase the production of 
collagen Type II, promote the migration of chondrocytes 
to the injured area and repair the damage by synthesizing 
the lost extracellular matrix (Horie et al. 2012; Iwata et al. 
1993). Based on the existing evidence, UC-MSC seems to 
be a highly promising therapeutic regimen for OA by the 
following mechanisms: inhibits the inflammatory response; 
inhibits the apoptosis mediated cell death; promotes the 
chondrocyte proliferation, and migration; promotes the 
extracellular matrix synthesis; and directly differentiates 
into chondrocytes or by inducing the differentiation of the 
native healthy chondroprogenitors into mature chondrocytes 
or both (Figure 1).
PRECLINICAL OUTCOME OF UC-MSC IN OA
The immunomodulatory and anti-inflammatory properties 
of MSCs have encouraged researchers to focus on the 
therapeutic application of MSCs for OA. In the past two 
FIGURE 1. Schematic representation of possible mechanism of UCMSCs in OA
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decades, many preclinical studies showed promising results 
of OA with the use of MSCs (MacFarlane et al. 2013). 
Intra-articular (IA) injection of MSCs for cartilage 
restoration has become a new cell therapy option for OA. 
Interestingly, Murphy et al. (2003) demonstrated that the 
bio-distribution of IA injection of MSCs has shown that 
the transplanted cells moved into the synovial membrane 
rather than the cartilage itself. This data suggests that MSCs 
have paracrine properties that are capable of chondrogenic 
differentiation. Some of the studies have proven the 
benefits of MSCs are due to its paracrine activity (Barry & 
Murphy 2013). Recently, Saulnier et al. (2015) confirmed 
the IA injection of UC-MSC in the rabbit model. The data 
showed that the IA injection might be more efficient in 
reducing inflammation and preventing OA progression by 
inducing chondrocytes to produce extracellular matrices 
and collagen types II, IX, and XI in the superficial and 
central regions (Akkiraju & Nohe 2015). Zhang et al. 
(2018) showed UC-MSCs treatment through articular cavity 
injection in a canine model, where two doses of 1×106 
UC-MSCs were injected and the therapeutic effect and 
mechanism of MSCs were observed. The results showed 
that the inflammatory reaction and joint effusion decreased 
after 7 days of post-transplantation. It was concluded that 
MSCs would be effective in treating OA by adjusting the 
repair response of the joint rather than replacing the 
damaged area directly.
Despite the allogeneic UC-MSCs shown promising 
therapeutic outcome in OA, the critical issue of the immune 
privilege needs to be assessed in the host of the animal 
model. The literature has outlined that UC-MSCs have 
peculiar immune-privileged properties, such as low 
expression of HLA-I and no expression of HLA-II (Kim et 
al. 2013; Liu et al. 2012). Furthermore, these cells are 
highly express HLA-G, which involve immune tolerance 
and also secrete various immunosuppressive biomolecules 
(TGF-β1, TNF-alpha, PEG2, IDO, NO) to suppress the 
primary and secondary immune cells, such as T, NK, B 
cell, DC, and neutrophils (Figure 2) (Kim et al. 2013). One 
recent finding demonstrated that immune-privileged status 
of UC-MSC has to be extended until specific lineage 
(chondrogenic) differentiation (Liu et al. 2012). Meanwhile, 
several studies have reported that rejection of allogeneic 
MSCs may hamper the tissue regeneration process 
(Eliopoulos et al. 2005; Huang et al. 2010; Tano et al. 
2016). Oliveira et al. (2017) reported that allogeneic MSCs 
were rejected from the host kidney tissue by not more than 
28 days after transplantation. This result may partially 
postulate that immuno-privileged status of MSC isreduced 
during differentiation and thus these cells were gradually 
eliminated by the host’s immune system. A similar 
paradigm has been confirmed in humans by de Windt et 
al. (2014) in a clinical trial for cartilage repair using 
allogeneic MSCs. Although an encouraging clinical 
outcome reported, no allogeneic cells were found at the 
repair site after 1- year post-transplantation. Overall, these 
reports declared that there are some limitations on the use 
of allogeneic MSCs, although recent findings have reported 
that the safety and some promising results promote their 
use as a therapeutic tool for OA.
FIGURE 2. Schematic representation of immunomodulatory effects of MSCs on innate and adoptive immune system
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OVERALL CLINICAL OUTCOME OF UC-MSC IN OA 
PATIENTS
In view of the fact that certain ethical concerns and poor 
chondrogenic property of the use of embryonic stem cell 
(ESC) and induced pluripotent stem cell (iPSC) are limited 
in OA treatment, it is thus inevitable to find an alternative 
type of stem cell source that would bypass the concerns of 
ESCs and iPSCs (Lee & Wang 2017). Recent clinical 
research suggests that human fetal tissues derived MSCs 
are more promising cell types to treat OA than other sources 
of MSCs. Various studies have proposed that human 
umbilical cord is the primary source for MSCs due to less 
ethical concern, easy harvest, expansion, high proliferation 
potency, low morbidity rate, higher migration potential 
non-invasive procedure and less side effects (Bartolucci 
et al. 2017). Moreover, UC-MSCs naturally have a high 
content of hyaluronic acid, glycosaminoglycans and 
collagens, which reflect the bio-composition of native 
cartilage tissue (Valiyaveettil et al. 2004). These UC-MSCs 
have several advantages than other existing MSCs and, 
therefore, researchers are encouraged to use UC-MSC for 
OA. According to the international clinical trial registry 
(Table 2) (www.clinicaltials.com), in 2019, 10 open clinical 
trials are to be conducted to address the safety, feasibility 
and therapeutic effect of UC-MSC in patients with OA. Most 
of the on-going clinical trials aim to deliver the MSCs 
through direct IA or surgical implantation in the presence 
or absence of scaffold (hyaluronic acid or platelet rich 
plasma) to assess the magnitude of cartilage regeneration 
(Wyles et al. 2015). An emerging database from phase I 
and II trials has reported that repeated dose (40×106) of 
UC-MSC in a patient with OA is safer and more logistically 
convenient than the autologous source. The same clinical 
trial has showed promising outcomes with repeated IA 
injection of UC-MSC, leading to a decrease in the level of 
pain and disability (Matas et al. 2019). The clinical 
application of UC-MSC for OA is still in its infancy and 
high-quality clinical trials are warranted to reproduce the 
outcome and resolve many questions, including dose 
(optimum number of cells) and mode of injection at each 
stage of OA.
FUTURE DIRECTION AND CONCLUSION
Clinical application of UC-MSC for OA treatment is still in 
infancy. Based on the preclinical and phase 1 or 2 clinical 
studies, UC-MSC based therapies have widely been 
explored to treat OA and hold promising therapeutic 
outcomes, including successful cartilage renewal and pain 
relief (Matas et al. 2019). However, an insufficient number 
of clinical trials on UC-MSC in cartilage regeneration 
means that there is currently no clear picture or evidence 
on the restoration of the native hyaline cartilage for 
permanent cure or at least long-term improvement. The 
clinical outcome of OA using UC-MSC is not consistent 
because of the technical challenge to produce UC-MSC in 
an optimized manner. Therefore, the development of 
universally standardized protocol is still detrimental. 
Meanwhile, the clinical improvement of UC-MSCs depends 
on the mode of injection and cell number (dose). 
Specifically, IA mode of implantation shows better clinical 
outcome. At the same time, the long-term consequence 
remains debatable. Very few clinical trials have shown that 
the therapeutic effect of MSC on OA is dose-dependent and 
declared that a large number of cells gives more beneficial 
effects. A randomized controlled study with a larger 
population would be an effective model to deal with the 
optimization of the dose required for cell therapy using 
UC-MSCs. Furthermore, a routine follow-up of the subjects 
is considered vital to assess the regeneration. This would 
ultimately provide better data to propose the target cell 
population are superior to other sources to handle OA. 
Several studies have emphasized that administration of 
UC-MSC directly to the joint space is associated with 
limitations such as massive cell death (cells are likely 
exposed to pathological environments such as hypoxic, 
acidic, nutritional deprivation, high concentration of 
inflammatory cytokines and reactive oxygen species) and 
risk of cell leakage (tendency of MSCs to migrate and 
because of the low level of cell engraftment) (Hached et 
al. 2017; Wyles et al. 2015; Zhang et al. 2018). To 
overcome these limitations, MSCs might be implanted into 
the abnormal microenvironments that have already been 
biochemically compromised. Nevertheless, cells have to 
be pre-treated or genetically modified to manage and 
withstand any pathophysiological environment. The 
generation of genetically modified MSCs is a more complex 
process and is more expensive, needs a sophisticated lab, 
and skilled personnel. Therefore, the current research 
prospected towards encapsulation of MSCs through three-
dimensional (3D) method using hydrogels or scaffolds (ex. 
collagen or hyaluronic acid) to enhance the retention of 
MSCs at the targeted tissues would be a feasible approach. 
Furthermore, the 3D scaffold may potentially improve the 
development of cartilage tissue. which is similar to native 
cartilage by providing an essential microenvironment and 
mechanical stimuli. In addition, encapsulated MSC together 
with growth factors (ex. platelet rich plasma) have shown 
better cartilage regeneration in a patient with OA; however, 
further extensive clinical studies are warranted to identify 
long-term beneficial and potential risks.
CONCLUSION
Although multiple published preclinical or clinical studies 
have stipulated the therapeutic outcome of UC-MSCs alone 
or together with scaffold or growth factors in OA, 
standardization of suitable dose of UC-MSCs, mode of 
injection, scaffold in OA with large sample size and long-
term follow ups are needed to reach a successful clinical 
translation. Considering the clinical instability and lack of 
effective mode of treatment for OA, this important approach 
could be explored further by bridging the current research 
gaps. Scientists in association with clinical specialists 
should explore and construct a concrete plan to 
understanding the pathophysiology and mechanism of 
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action using UC-MSCs, which have already had a 
considerable impact. 
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